Bad Vilbel, Germany

David Voigtlaender

USPTO Granted Patents = 1 

Average Co-Inventor Count = 17.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of David Voigtlaender

Introduction: David Voigtlaender, an accomplished inventor based in Bad Vilbel, Germany, has made significant contributions to the field of pharmaceuticals. His expertise is particularly evident in his work on a complex chemical compound that has the potential to enhance drug formulation.

Latest Patents: Voigtlaender holds a patent for the "Method for preparing 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde (E)-oxime (asoprisnil)." This invention pertains to a method that enables the reliable and reproducible production of asoprisnil, ensuring that it can be manufactured on both pilot and commercial scales. This compound is noted for its excellent physical stability, making it particularly suitable for the creation of solid pharmaceutical forms like tablets and coated tablets.

Career Highlights: Voigtlaender is currently associated with Bayer Pharma Aktiengesellschaft, a leading company in pharmaceutical innovation. His work contributes to Bayer's commitment to developing effective medications that enhance patient care and treatment options.

Collaborations: Throughout his career, Voigtlaender has collaborated with talented professionals such as Detlef Grawe and Sabine Gliesing. These collaborations have likely enhanced the quality and impact of the innovative work produced in Bayer's research environment.

Conclusion: David Voigtlaender exemplifies the spirit of innovation within the pharmaceutical industry. His patent and ongoing contributions not only reflect his dedication but also signify advancements that could strengthen drug manufacturing processes and improve patient outcomes. As the pharmaceutical landscape continues to evolve, inventors like Voigtlaender play a pivotal role in shaping the future of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…